What is Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS)?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported diluted earnings per share of -$5.90 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Corbus Pharmaceuticals Holdings (CRBP) Financials

CRBP NASDAQ

FY2025 annual

Net Income -$78.5M n/m YoY

EPS (Diluted) -$5.90 n/m YoY

Free Cash Flow -$64.5M n/m YoY

Operating Cash Flow -$64.5M n/m YoY

Market Cap $80.3M as of Oct 27, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.8x on $102.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CRBP SEC filings page.

This page shows Corbus Pharmaceuticals Holdings, Inc. (CRBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CRBP FY2025 2026-10-25

Corbus is a development-stage business whose expanding research spend produces losses, while external financing supports liquidity.

In FY2025, operating cash flow was -$64.5M and free cash flow was -$64.5M, showing little cash effect from capital expenditure. That near-match with the $78.5M net loss indicates earnings are not materially separated from cash use by noncash effects or working-capital movement.

R&D spending rose 117.5% to $70.1M in FY2025, making development investment the dominant visible cost. The net loss was $78.5M in FY2025 versus $40.2M in FY2024, so heavier research commitment translated into greater reported losses rather than operating break-even.

FY2025 liabilities were $20.7M against $147.5M of equity, leaving a predominantly equity-funded balance sheet. The liquidity measure stood at 30.4 months of reported annual outflow while financing cash flow was positive, indicating cash resources were supported outside operations.

Financial Health Signals

Financial health score not available

Corbus Pharmaceuticals Holdings, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Corbus Pharmaceuticals Holdings, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $78.5M while operations used $64.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$36.1M

YoYn/m

QoQn/m

Corbus Pharmaceuticals Holdings, Inc.'s EBITDA was -$36.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income

-$35.0M

YoYn/m

QoQn/m

Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $35.0M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$1.81

QoQn/m

Corbus Pharmaceuticals Holdings, Inc. earned -$1.81 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$29.6M

YoYn/m

QoQn/m

Corbus Pharmaceuticals Holdings, Inc. recorded an outflow of $29.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt

$23.4M

YoY+16.6%

QoQ-8.9%

5Y CAGR-8.3%

10Y CAGR+0.6%

Corbus Pharmaceuticals Holdings, Inc. held $23.4M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

19M

QoQ+4.4%

Corbus Pharmaceuticals Holdings, Inc. had 19M shares outstanding in Q2 2026. Against the prior quarter it is up 4.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-34.3%

YoY-18.4pp

QoQ-16.1pp

Corbus Pharmaceuticals Holdings, Inc.'s quarterly ROE was -34.3% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 18.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 16.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$31.2M

YoY+105.3%

QoQ+57.3%

Corbus Pharmaceuticals Holdings, Inc. invested $31.2M in research and development in Q2 2026. This represents an increase of 105.3% from the same quarter a year earlier. Against the prior quarter it is up 57.3%.

Capital Expenditures

$6K

YoYn/m

QoQ0.0%

Corbus Pharmaceuticals Holdings, Inc. invested $6K in capex in Q2 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. It is unchanged from the prior quarter.

Share Buybacks

Not reported for Q2 2026.

CRBP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CRBP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	N/A	N/A	N/A	$0-100.0%	$882K-77.6%	$3.9M-89.1%	$36.1M+649.5%	$4.8M+97.6%	$2.4M+27.7%	$1.9M+194.8%	$648K	N/A	N/A
R&D Expenses	N/A	$70.1M+117.5%	$32.2M+3.4%	$31.2M+93.1%	$16.1M-55.7%	$36.4M-62.9%	$98.3M+9.7%	$89.6M+84.3%	$48.6M+86.7%	$26.0M+68.7%	$15.4M+162.1%	$5.9M+369.0%	$1.3M+496.0%	$211K
SG&A Expenses	N/A	$15.2M-7.8%	$16.5M+18.6%	$13.9M-25.6%	$18.7M-8.5%	$20.4M-28.3%	$28.5M+20.5%	$23.6M+82.5%	$13.0M+44.5%	$9.0M+38.8%	$6.5M+78.8%	$3.6M+159.7%	$1.4M+301.5%	$347K
Operating Income	N/A	-$85.3Mn/m	-$48.7Mn/m	-$45.1Mn/m	-$39.8Mn/m	-$56.0Mn/m	-$122.8Mn/m	-$77.1Mn/m	-$56.7Mn/m	-$32.6Mn/m	-$20.0Mn/m	-$8.9Mn/m	-$2.6Mn/m	-$557K
EBITDA	N/A	-$85.1Mn/m	-$48.1Mn/m	-$44.4Mn/m	-$39.1Mn/m	-$55.0Mn/m	-$121.7Mn/m	-$76.4Mn/m	-$56.3Mn/m	-$32.3Mn/m	-$19.9Mn/m	-$8.8Mn/m	-$2.6M	N/A
Interest Expense	N/A	$0-100.0%	$1.8M-52.6%	$3.8M+22.7%	$3.1M+14.3%	$2.7M+140.5%	$1.1Mn/m	$0	N/A	$4K+16.6%	$3K+27.7%	$2K-89.8%	$24K-46.8%	$45K
Income Tax	N/A	$0n/m	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$78.5Mn/m	-$40.2Mn/m	-$44.6Mn/m	-$42.3Mn/m	-$45.6Mn/m	-$111.3Mn/m	-$71.5Mn/m	-$55.7Mn/m	-$32.4Mn/m	-$20.0Mn/m	-$8.9Mn/m	-$2.5Mn/m	-$602K
EPS (Basic)	N/A	-$5.90n/m	-$3.68	-$10.31	-$10.15	-$11.15	-$1.42n/m	-$1.12n/m	-$0.98n/m	-$0.65n/m	-$0.49n/m	-$0.28	-$0.13	-$0.09
EPS (Diluted)	-$6.11	-$5.90n/m	-$3.68	-$10.31	-$10.15	-$11.15	-$1.42n/m	-$1.12n/m	-$0.98n/m	-$0.65n/m	-$0.49n/m	-$0.28	-$0.13	-$0.09
Diluted Shares (Avg)	N/A	13M+22.0%	11M	4M	4M	4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$31.2M+105.3%	$19.8M+26.7%	N/A	$20.9M+93.0%	$15.2M+121.2%	$15.6M+171.5%	N/A	$10.8M+65.0%
SG&A Expenses	$5.0M+26.5%	$4.5M+8.5%	N/A	$3.6M-24.3%	$4.0M-3.8%	$4.1M+7.0%	N/A	$4.7M+59.9%
Operating Income	-$36.2Mn/m	-$24.3Mn/m	N/A	-$24.4Mn/m	-$19.2Mn/m	-$19.8Mn/m	N/A	-$15.5Mn/m
EBITDA	-$36.1Mn/m	-$24.3Mn/m	N/A	-$24.3Mn/m	-$19.1Mn/m	-$19.7Mn/m	N/A	-$15.3Mn/m
Interest Expense	N/A	N/A	N/A	$0-100.0%	$0-100.0%	$0-100.0%	N/A	$400K-60.0%
Net Income	-$35.0Mn/m	-$23.0Mn/m	N/A	-$23.3Mn/m	-$17.7Mn/m	-$17.0Mn/m	N/A	-$13.8Mn/m
EPS (Basic)	-$1.81	-$1.23	-$1.17n/m	-$1.90n/m	-$1.44n/m	-$1.39n/m	-$0.76n/m	-$1.15
EPS (Diluted)	-$1.81	-$1.23	-$1.17n/m	-$1.90n/m	-$1.44n/m	-$1.39n/m	-$0.76n/m	-$1.15
Diluted Shares (Avg)	19M	19M	N/A	12M+2.4%	12M+10.7%	12M+46.8%	N/A	12M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

CRBP Balance Sheet

CRBP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$168.2M+7.9%	$155.9M+451.4%	$28.3M-57.4%	$66.3M-38.4%	$107.7M+5.3%	$102.3M+108.2%	$49.1M+4.6%	$47.0M-29.8%	$67.0M+274.4%	$17.9M+38.9%	$12.9M+95.1%	$6.6M+2060.5%	$306K
Current Assets	$167.0M+9.1%	$153.0M+549.7%	$23.5M-60.9%	$60.2M-39.9%	$100.2M+8.8%	$92.1M+141.3%	$38.2M-13.8%	$44.2M-32.5%	$65.5M+276.4%	$17.4M+36.9%	$12.7M+94.6%	$6.5M+2038.3%	$306K
Cash & Equivalents	$28.5M+65.7%	$17.2M+25.3%	$13.7M-19.3%	$17.0M-32.0%	$25.0M-70.7%	$85.4M+169.1%	$31.7M-24.0%	$41.7M-33.2%	$62.5M+317.1%	$15.0M+21.5%	$12.3M+97.0%	$6.3M+1966.7%	$303K
Short-Term Investments	$134.8M+2.2%	$131.9M+1736.0%	$7.2M-83.0%	$42.2M-41.9%	$72.6Mn/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Total Liabilities	$20.7M+53.8%	$13.5M-61.8%	$35.2M+5.6%	$33.3M-13.7%	$38.6M-32.3%	$57.0M+32.7%	$43.0M+120.8%	$19.5M+111.7%	$9.2M+2.5%	$9.0M+130.5%	$3.9M+427.1%	$738K-64.7%	$2.1M
Current Liabilities	$20.7M+75.1%	$11.8M-62.9%	$31.9M+152.3%	$12.6M-25.7%	$17.0M-46.7%	$31.9M-8.6%	$34.9M+92.9%	$18.1M+120.5%	$8.2M-7.8%	$8.9M+145.1%	$3.6M+391.8%	$738K+13.7%	$649K
Non-Current Liabilities	$0-100.0%	$1.6M-50.3%	$3.3M-84.1%	$20.7M-4.3%	$21.6M-14.0%	$25.1M+210.3%	$8.1M+488.5%	$1.4M+39.0%	$990K+1307.0%	$70K-73.0%	$260Kn/m	$0-100.0%	$1.4M
Long-Term Debt	N/A	N/A	$0-100.0%	$16.0M+2.2%	$15.6M-13.3%	$18.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$147.5M+3.6%	$142.4Mn/m	-$6.9M-120.9%	$33.0M-52.3%	$69.1M+52.6%	$45.3M+635.3%	$6.2M-77.6%	$27.5M-52.4%	$57.8M+547.9%	$8.9M-0.7%	$9.0M+53.3%	$5.9Mn/m	-$1.8M
Retained Earnings	-$555.4Mn/m	-$476.9Mn/m	-$436.7Mn/m	-$392.1Mn/m	-$349.7Mn/m	-$304.1Mn/m	-$192.8Mn/m	-$121.4Mn/m	-$65.7Mn/m	-$33.3Mn/m	-$13.3Mn/m	-$4.4Mn/m	-$1.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$127.0M+1.5%	$144.5M+3.3%	$168.2M+7.9%	$109.5M-33.3%	$125.1M-17.7%	$139.9M+11.3%	$155.9M+451.4%	$164.2M+352.5%
Current Assets	$122.8M-0.1%	$143.6M+4.5%	$167.0M+9.1%	$107.6M-33.1%	$122.8M-17.2%	$137.4M+12.9%	$153.0M+549.7%	$160.9M+415.6%
Cash & Equivalents	$23.4M+16.6%	$25.7M+35.8%	$28.5M+65.7%	$27.0M+38.9%	$20.0M-15.4%	$18.9M+34.0%	$17.2M+25.3%	$19.4M+72.7%
Short-Term Investments	$94.6M-2.0%	$112.6M-1.2%	$134.8M+2.2%	$77.0M-45.0%	$96.5M-21.7%	$113.9M+7.4%	$131.9M+1736.0%	$139.9M+700.4%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Total Liabilities	$24.7M+75.6%	$18.1M+41.4%	$20.7M+53.8%	$17.4M+27.0%	$14.1M-46.7%	$12.8M-55.4%	$13.5M-61.8%	$13.7M-62.0%
Current Liabilities	$21.5M+61.1%	$18.1M+56.1%	$20.7M+75.1%	$17.1M+46.8%	$13.3M-44.4%	$11.6M-55.2%	$11.8M-62.9%	$11.6M-63.1%
Non-Current Liabilities	$3.3M+329.0%	$0-100.0%	$0-100.0%	$307K-85.0%	$761K-69.0%	$1.2M-57.8%	$1.6M-50.3%	$2.0M-53.8%
Total Equity	$102.2M-7.9%	$126.3M-0.6%	$147.5M+3.6%	$92.1M-38.8%	$111.0M-11.6%	$127.1M+31.1%	$142.4Mn/m	$150.5M+48136.5%
Retained Earnings	-$613.4Mn/m	-$578.4Mn/m	-$555.4Mn/m	-$534.9Mn/m	-$511.5Mn/m	-$493.9Mn/m	-$476.9Mn/m	-$467.4Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CRBP Cash Flow Statement

CRBP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$86.7M	-$64.5Mn/m	-$41.8Mn/m	-$36.1Mn/m	-$37.5Mn/m	-$48.2Mn/m	-$99.7Mn/m	-$45.7Mn/m	-$30.1Mn/m	-$27.8Mn/m	-$13.6Mn/m	-$4.6Mn/m	-$2.4Mn/m	-$367K
Depreciation & Amortization	N/A	$233K-60.4%	$588K-8.3%	$641K-16.0%	$763K-23.7%	$1000K-11.0%	$1.1M+52.0%	$739K+49.7%	$494K+93.2%	$256K+191.6%	$88K+99.5%	$44K+322.3%	$10K	N/A
Stock-Based Compensation	N/A	$6.3M+2.3%	$6.1M+77.1%	$3.5M-39.3%	$5.7M-39.7%	$9.5M-23.9%	$12.5M+4.0%	$12.0M+57.5%	$7.6M+33.6%	$5.7M+80.0%	$3.2M+174.3%	$1.2M+497.2%	$193K+3044.8%	$6K
Capital Expenditures	N/A	$7Kn/m	$0n/m	$0-100.0%	$13K-75.2%	$54K-88.8%	$484K-82.3%	$2.7M+19.2%	$2.3M+225.2%	$707K+100.4%	$353K+209.6%	$114K+76.9%	$64K	N/A
Free Cash Flow	N/A	-$64.5Mn/m	-$41.8Mn/m	-$36.1Mn/m	-$37.6Mn/m	-$48.2Mn/m	-$100.2Mn/m	-$48.5Mn/m	-$32.4Mn/m	-$28.5Mn/m	-$13.9Mn/m	-$4.7Mn/m	-$2.4M	N/A
Investing Cash Flow	$3.2M	-$1.6Mn/m	-$121.3M-440.4%	$35.6M+18.5%	$30.1Mn/m	-$73.4Mn/m	-$484Kn/m	-$2.7Mn/m	-$2.3Mn/m	-$707K	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$77.4M-53.5%	$166.6Mn/m	-$2.8Mn/m	-$534K-100.9%	$60.8M-60.7%	$154.9M+302.7%	$38.5M+236.8%	$11.4M-85.0%	$76.0M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$29.6Mn/m	-$25.6Mn/m	-$15.9Mn/m	-$15.6Mn/m	-$16.6Mn/m	-$16.4Mn/m	-$10.9Mn/m	-$13.9Mn/m
Depreciation & Amortization	$50K-50.0%	$49K-39.5%	$49K-63.4%	$100K-50.0%	$100K-50.0%	$81K-46.7%	$134K-9.5%	$200K0.0%
Stock-Based Compensation	$1.8M+15.5%	$1.9M+11.8%	N/A	$2K-29.5%	$1.6M+121250.9%	$1.7M+74.5%	N/A	$2K-99.7%
Capital Expenditures	$6Kn/m	$6Kn/m	N/A	N/A	$0	$0	N/A	N/A
Free Cash Flow	-$29.6Mn/m	-$25.6Mn/m	N/A	N/A	-$16.6M	-$16.4M	N/A	N/A
Investing Cash Flow	$18.3M+2.9%	$22.5M+23.9%	-$57.1M-754.6%	$19.6Mn/m	$17.7Mn/m	$18.1Mn/m	$8.7M-16.0%	-$15.4M-241.0%
Financing Cash Flow	N/A	N/A	$74.6Mn/m	$2.9M-88.6%	$0-100.0%	$0-100.0%	-$13Kn/m	$25.0Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CRBP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CRBP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Margin	N/A	N/A	N/A	N/A	-6350.1%	-3119.2%	-213.3%	-1176.8%	-1334.4%	-1045.6%	-1365.5%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	-5176.4%	-2826.1%	-197.7%	-1154.5%	-1328.6%	-1046.3%	-1365.1%	N/A	N/A
Return on Equity	-53.2%-25.0pp	-28.2%	N/A	-128.4%-62.3pp	-66.0%+179.7pp	-245.8%+914.7pp	-1160.4%-958.2pp	-202.3%-146.2pp	-56.1%+168.1pp	-224.2%-125.7pp	-98.5%-55.2pp	-43.3%	N/A
Return on Assets	-46.7%-20.9pp	-25.8%+132.0pp	-157.8%-93.9pp	-63.9%-21.5pp	-42.4%+66.4pp	-108.8%+36.6pp	-145.4%-26.9pp	-118.5%-70.1pp	-48.4%+63.4pp	-111.8%-43.1pp	-68.7%-30.3pp	-38.5%+158.7pp	-197.2%
Current Ratio	8.07-4.9x	12.94+12.2x	0.74-4.0x	4.76-1.1x	5.89+3.0x	2.89+1.8x	1.09-1.4x	2.45-5.5x	7.98+6.0x	1.96-1.5x	3.50-5.3x	8.85+8.4x	0.47
Debt-to-Equity	N/A	N/A	N/A	0.48+0.3x	0.23-0.2x	0.40	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Liabilities-to-Equity	0.140.0x	0.09	N/A	1.01+0.5x	0.56-0.7x	1.26-5.7x	6.98+6.3x	0.71+0.5x	0.16-0.8x	1.01+0.6x	0.43+0.3x	0.13	N/A
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.010.0x	0.04-0.7x	0.74+0.6x	0.10+0.1x	0.04-0.1x	0.11+0.1x	0.05	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	-5471.0%	-2544.2%	-134.1%	-671.2%	-1168.1%	-728.5%	-730.9%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-34.3%-18.4pp	-18.2%-4.8pp	N/A	-25.3%-16.2pp	-15.9%-7.9pp	-13.4%-6.3pp	N/A	-9.2%+3213.0pp
Return on Assets	-27.6%-13.5pp	-15.9%-3.8pp	N/A	-21.3%-12.9pp	-14.1%-7.5pp	-12.1%-6.6pp	N/A	-8.4%+19.3pp
Current Ratio	5.71-3.5x	7.92-3.9x	8.07-4.9x	6.31-7.5x	9.21+3.0x	11.82+7.1x	12.94+12.2x	13.84+12.9x
Liabilities-to-Equity	0.24+0.1x	0.140.0x	0.140.0x	0.19+0.1x	0.13-0.1x	0.10-0.2x	0.09	0.09-115.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Corbus Pharmaceuticals Holdings, Inc. CRBP	FY2025	N/A	-$78.5M	N/A	$80.3M	—
Biomea Fusion, Inc. BMEA	FY2025	N/A	-$61.8M	N/A	$46.4M	—
Pyxis Oncology, Inc. PYXS	FY2025	$13.9M	-$79.6M	N/A	$219.8M	57/100
KALA BIO, Inc. KALA	FY2025	$0	-$27.0M	N/A	$3.4M	—
Equillium, Inc. EQ	FY2025	N/A	-$22.4M	N/A	$86.2M	—
Fate Therapeutics, Inc. FATE	FY2025	$6.6M	-$136.3M	N/A	$248.0M	55/100

Where Corbus Pharmaceuticals Holdings, Inc. Ranks

Frequently Asked Questions

Is Corbus Pharmaceuticals Holdings, Inc. profitable?

No, Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported a net loss of $78.5M in fiscal year 2025.

What is Corbus Pharmaceuticals Holdings, Inc.'s EBITDA?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) had EBITDA of -$85.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Corbus Pharmaceuticals Holdings, Inc.'s return on equity (ROE)?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a return on equity of -53.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Corbus Pharmaceuticals Holdings, Inc.'s free cash flow?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) recorded an outflow of $64.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Corbus Pharmaceuticals Holdings, Inc.'s operating cash flow?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) recorded an outflow of $64.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Corbus Pharmaceuticals Holdings, Inc.'s total assets?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) had $168.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Corbus Pharmaceuticals Holdings, Inc.'s capital expenditures?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Corbus Pharmaceuticals Holdings, Inc. spend on research and development?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) invested $70.1M in research and development during fiscal year 2025.

How many shares does Corbus Pharmaceuticals Holdings, Inc. have outstanding?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) had 18M shares outstanding as of fiscal year 2025.

What is Corbus Pharmaceuticals Holdings, Inc.'s current ratio?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) had a current ratio of 8.07 as of fiscal year 2025, which is generally considered healthy.

What is Corbus Pharmaceuticals Holdings, Inc.'s liabilities-to-equity ratio?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) had a liabilities-to-equity ratio of 0.14 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is Corbus Pharmaceuticals Holdings, Inc.'s return on assets (ROA)?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) had a return on assets of -46.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Corbus Pharmaceuticals Holdings, Inc.'s P/E ratio?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $80.3M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Corbus Pharmaceuticals Holdings, Inc.'s price-to-sales ratio?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $80.3M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Corbus Pharmaceuticals Holdings, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Corbus Pharmaceuticals Holdings, Inc. (CRBP) held $163.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $64.5M over that year. Dividing the one by the other, the reported balance equals about 30 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Corbus Pharmaceuticals Holdings, Inc.'s Piotroski F-Score?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Corbus Pharmaceuticals Holdings, Inc.'s earnings high quality?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported a net loss of $78.5M while operations used $64.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.